Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rogers, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rogers, S. L.
NEUROLOGY 1998;50:136-145
© 1998 American Academy of Neurology

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

S. L. Rogers, PhD, M. R. Farlow, MD, R. S. Doody, MD PhD, R. Mohs, PhD, L. T. Friedhoff, MD, PhD and Donepezil Study Group*

From Eisai Inc. (Drs. Rogers and Friedhoff), Teaneck, NJ; the Indiana University School of Medicine (Dr. Farlow), Indianapolis, IN; Baylor College of Medicine (Dr. Doody), Houston, TX; and the Mount Sinai Medical Center (Dr. Mohs), New York, NY.

Address correspondence and reprint requests to Dr. L. T. Friedhoff, Eisai Inc., Glenpointe Centre West, 500 Frank W. Burr Blvd., Teaneck, NJ 07666-6741.

The efficacy and safety of donepezil as a treatment for patients with mild to moderate Alzheimer's disease (AD) was investigated in a multicenter, double-blind study. Patients were randomly assigned to treatment with placebo(n = 162), 5 mg/d donepezil (n = 154), or 10 mg/d donepezil (n = 157) for 24 weeks followed by a 6-week, single-blind placebo washout. The primary efficacy measures were the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog) and the Clinician's Interview Based Assessment of Change-Plus (CIBIC plus), with the Mini-Mental State Examination (MMSE), Clinical Dementia Rating Scale-Sum of the Boxes (CDR-SB), and patient rated Quality of Life (QoL) used as secondary measures. Cognitive function, as measured by the ADAS-cog, was significantly improved in the 5- and 10-mg/d donepezil groups as compared with the placebo group at weeks 12, 18, and 24. Clinician's global ratings on the CIBIC plus also improved in both the 5- and 10-mg/d donepezil groups relative to placebo. At the end of the 6-week placebo washout phase, ADAS-cog scores and CIBIC plus ratings were not significantly different for the three groups. Significant treatment benefits were also observed consistently in both the 5- and 10-mg/d groups on the MMSE and the CDR-SB, but there was no consistent effect on the patient-rated QoL. Cholinergic side effects (primarily diarrhea, nausea, and vomiting) were reported more often in the 10-mg/d group than either the 5-mg/d or placebo groups. Side effects were transient and generally mild in severity. These data indicate that donepezil is a well-tolerated drug that improves cognition and global function in patients with mild to moderate AD.


*See the Appendix on page 144 for a listing of the members of the Donepezil Group.

Supported by Eisai Inc., Teaneck NJ, U.S.A. and Eisai Co. Ltd., Tokyo, Japan.

Received March 12, 1997. Accepted in final form August 20, 1997.




This article has been cited by other articles:


Home page
ANN INTERN MEDHome page
A. Qaseem, V. Snow, J. T. Cross Jr., M. A. Forciea, R. Hopkins Jr., P. Shekelle, A. Adelman, D. Mehr, K. Schellhase, D. Campos-Outcalt, et al.
Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians
Ann Intern Med, March 4, 2008; 148(5): 370 - 378.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
P. Raina, P. Santaguida, A. Ismaila, C. Patterson, D. Cowan, M. Levine, L. Booker, and M. Oremus
Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
Ann Intern Med, March 4, 2008; 148(5): 379 - 397.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
P. Bentley, J. Driver, and R. J. Dolan
Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health
Brain, February 1, 2008; 131(2): 409 - 424.
[Abstract] [Full Text] [PDF]


Home page
AM J ALZHEIMERS DIS OTHER DEMENHome page
R. J. Caselli and R. Yaari
Medical Management of Frontotemporal Dementia
American Journal of Alzheimer's Disease and Other Dementias, January 1, 2008; 22(6): 489 - 498.
[Abstract] [PDF]


Home page
AJGPHome page
J. R. Tinklenberg, H. C. Kraemer, K. Yaffe, L. Ross, J. Sheikh, J. W. Ashford, J. A. Yesavage, and J. L. Taylor
Donepezil Treatment and Alzheimer Disease: Can the Results of Randomized Clinical Trials Be Applied to Alzheimer Disease Patients in Clinical Practice?
Am J Geriatr Psychiatry, November 1, 2007; 15(11): 953 - 960.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Mozayan and T. J. F. Lee
Statins prevent cholinesterase inhibitor blockade of sympathetic {alpha}7-nAChR-mediated currents in rat superior cervical ganglion neurons
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1737 - H1744.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
K. A. Swanson and R. M. Carnahan
Dementia and Comorbidities: An Overview of Diagnosis and Management
Journal of Pharmacy Practice, August 1, 2007; 20(4): 296 - 317.
[Abstract] [PDF]


Home page
JNMHome page
H. Matsuda
Role of Neuroimaging in Alzheimer's Disease, with Emphasis on Brain Perfusion SPECT
J. Nucl. Med., August 1, 2007; 48(8): 1289 - 1300.
[Abstract] [Full Text] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
J. P. Rowland, J. Rigby, A. C. Harper, and R. Rowland
Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol
Advan. Psychiatr. Treat., May 1, 2007; 13(3): 178 - 184.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
A. S. Chappell, C. Gonzales, J. Williams, M. M. Witte, R. C. Mohs, and R. Sperling
AMPA potentiator treatment of cognitive deficits in Alzheimer disease
Neurology, March 27, 2007; 68(13): 1008 - 1012.
[Abstract] [Full Text] [PDF]


Home page
AM J ALZHEIMERS DIS OTHER DEMENHome page
L. Rozzini, B. V. Chilovi, E. Bertoletti, M. Conti, I. Delrio, M. Trabucchi, and A. Padovani
Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study.
American Journal of Alzheimer's Disease and Other Dementias, February 1, 2007; 22(1): 42 - 47.
[Abstract] [PDF]


Home page
Journal of Pharmacy PracticeHome page
A. T. Blaszczyk and M. Mathys
Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia
Journal of Pharmacy Practice, February 1, 2007; 20(1): 13 - 28.
[Abstract] [PDF]


Home page
AM J ALZHEIMERS DIS OTHER DEMENHome page
J. F. Paskavitz, J. J. Gunstad, and J. E. Samuel
Clock Drawing and Frontal Lobe Behavioral Effects of Memantine in Alzheimer's Disease: A Rater-Blinded Study
American Journal of Alzheimer's Disease and Other Dementias, January 1, 2007; 21(6): 454 - 459.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
A. Burns and J. O'Brien
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
J Psychopharmacol, November 1, 2006; 20(6): 732 - 755.
[Abstract] [PDF]


Home page
Evid. Based Ment. HealthHome page
J. M Ringman
Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer's disease.
Evid. Based Ment. Health, November 1, 2006; 9(4): 104 - 104.
[Full Text] [PDF]


Home page
BrainHome page
H.-W. Klafki, M. Staufenbiel, J. Kornhuber, and J. Wiltfang
Therapeutic approaches to Alzheimer's disease
Brain, November 1, 2006; 129(11): 2840 - 2855.
[Abstract] [Full Text] [PDF]


Home page
GENES CELLSHome page
N. Kaneko, H. Okano, and K. Sawamoto
Role of the cholinergic system in regulating survival of newborn neurons in the adult mouse dentate gyrus and olfactory bulb.
Genes Cells, October 1, 2006; 11(10): 1145 - 1159.
[Abstract] [Full Text] [PDF]


Home page
Age AgeingHome page
S. Lopez-Pousa, J. G. Olmo, J. V. Franch, A. T. Estrada, O. S. Cors, I. P. Nierga, and E. Gelada-Batlle
Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
Age Ageing, July 1, 2006; 35(4): 365 - 371.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
S. Gillette-Guyonnet, S. Andrieu, F. Cortes, F. Nourhashemi, C. Cantet, P.-J. Ousset, E. Reynish, H. Grandjean, and B. Vellas
Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors.
J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2006; 61(5): 516 - 520.
[Abstract] [Full Text] [PDF]


Home page
J. Neuropsychiatry Clin. Neurosi.Home page
J. A. Bourgeois, F. Farzin, J. A. Brunberg, F. Tassone, P. Hagerman, L. Zhang, D. Hessl, and R. Hagerman
Dementia With Mood Symptoms in a Fragile X Premutation Carrier With the Fragile X-Associated Tremor/Ataxia Syndrome: Clinical Intervention With Donepezil and Venlafaxine
J Neuropsychiatry Clin Neurosci, May 1, 2006; 18(2): 171 - 177.
[Abstract] [Full Text] [PDF]


Home page
J Geriatr Psychiatry NeurolHome page
H. Kazui, N. Hirono, M. Hashimoto, Y. Nakano, K. Matsumoto, Y. Takatsuki, E. Mori, Y. Ikejiri, and M. Takeda
Symptoms Underlying Unawareness of Memory Impairment in Patients With Mild Alzheimer's Disease
J Geriatr Psychiatry Neurol, March 1, 2006; 19(1): 3 - 12.
[Abstract] [PDF]


Home page
AM J ALZHEIMERS DIS OTHER DEMENHome page
D. M. Marseille and D. H.S. Silverman
Recognition and treatment of Alzheimer's disease: A case-based review
American Journal of Alzheimer's Disease and Other Dementias, March 1, 2006; 21(2): 119 - 125.
[Abstract] [PDF]


Home page
Evid Based Complement Alternat MedHome page
H. Joshi and M. Parle
Brahmi rasayana Improves Learning and Memory in Mice.
Evid. Based Complement. Altern. Med., March 1, 2006; 3(1): 79 - 85.
[Abstract] [Full Text] [PDF]


Home page
J Atten DisordHome page
R. L. Doyle, J. Frazier, T. J. Spencer, D. Geller, J. Biederman, and T. Wilens
Donepezil in the Treatment of ADHD-Like Symptoms in Youths With Pervasive Developmental Disorder: A Case Series.
J Atten Disord, February 1, 2006; 9(3): 543 - 549.
[Abstract] [PDF]


Home page
AJGPHome page
T. T.J. Kircher, M. Erb, W. Grodd, and D. T. Leube
Cortical Activation During Cholinesterase-Inhibitor Treatment in Alzheimer Disease: Preliminary Findings From a Pharmaco-fMRI Study
Am J Geriatr Psychiatry, November 1, 2005; 13(11): 1006 - 1013.
[Abstract] [Full Text] [PDF]


Home page
Psychiatr. Bull.Home page
S. Simpson, D. Beavis, A. Leddy, S. Ball, and I. Johnson
Naturalistic audit of NICE criteria for the use of cholinesterase inhibitors
Psychiatr. Bull., November 1, 2005; 29(11): 410 - 412.
[Abstract] [Full Text] [PDF]


Home page
Clin TrialsHome page
C. Xiong, K. Yu, F. Gao, Y. Yan, and Z. Zhang
Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial
Clinical Trials, October 1, 2005; 2(5): 387 - 393.
[Abstract] [PDF]


Home page
NeurologyHome page
M. R. Farlow
Moderate to severe Alzheimer disease: Definition and clinical relevance
Neurology, September 27, 2005; 65(6_suppl_3): S1 - S4.
[Full Text]


Home page
NeurologyHome page
H. H. Feldman and M. Woodward
The staging and assessment of moderate to severe Alzheimer disease
Neurology, September 27, 2005; 65(6_suppl_3): S10 - S17.
[Abstract] [Full Text]


Home page
NeurologyHome page
H. Fillit
Cost consequences and cost benefits of treating patients with moderate to severe Alzheimer disease
Neurology, September 27, 2005; 65(6_suppl_3): S31 - S33.
[Full Text]


Home page
BMJHome page
H. Kaduszkiewicz, T. Zimmermann, H.-P. Beck-Bornholdt, and H. van den Bussche
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials
BMJ, August 6, 2005; 331(7512): 321 - 327.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
B Ravina, M Putt, A Siderowf, J T Farrar, M Gillespie, A Crawley, H H Fernandez, M M Trieschmann, S Reichwein, and T Simuni
Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study
J. Neurol. Neurosurg. Psychiatry, July 1, 2005; 76(7): 934 - 939.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. C. Petersen, R. G. Thomas, M. Grundman, D. Bennett, R. Doody, S. Ferris, D. Galasko, S. Jin, J. Kaye, A. Levey, et al.
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
N. Engl. J. Med., June 9, 2005; 352(23): 2379 - 2388.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
R Vandenberghe and J Tournoy
Cognitive aging and Alzheimer's disease
Postgrad. Med. J., June 1, 2005; 81(956): 343 - 352.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
M. Hashimoto, H. Kazui, K. Matsumoto, Y. Nakano, M. Yasuda, and E. Mori
Does Donepezil Treatment Slow the Progression of Hippocampal Atrophy in Patients With Alzheimer's Disease?
Am J Psychiatry, April 1, 2005; 162(4): 676 - 682.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
N I Bohnen, D I Kaufer, R Hendrickson, L S Ivanco, B J Lopresti, R A Koeppe, C C Meltzer, G Constantine, J G Davis, C A Mathis, et al.
Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 315 - 319.
[Abstract] [Full Text] [PDF]


Home page
JAOA: Journal of the American Osteopathic AssociationHome page
J. M. Ellis
Cholinesterase Inhibitors in the Treatment of Dementia
J Am Osteopath Assoc, March 1, 2005; 105(3): 145 - 158.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
N. D Chiaravalloti, J. DeLuca, N. B Moore, and J. H Ricker
Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial
Multiple Sclerosis, February 1, 2005; 11(1): 58 - 68.
[Abstract] [PDF]


Home page
BrainHome page
C. H. Salmond, D. A. Chatfield, D. K. Menon, J. D. Pickard, and B. J. Sahakian
Cognitive sequelae of head injury: involvement of basal forebrain and associated structures
Brain, January 1, 2005; 128(1): 189 - 200.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
K. M. Langa, N. L. Foster, and E. B. Larson
Mixed Dementia: Emerging Concepts and Therapeutic Implications
JAMA, December 15, 2004; 292(23): 2901 - 2908.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
B. Seltzer, P. Zolnouni, M. Nunez, R. Goldman, D. Kumar, J. Ieni, S. Richardson, and for the Donepezil "402" Study Group
Efficacy of Donepezil in Early-Stage Alzheimer Disease: A Randomized Placebo-Controlled Trial
Arch Neurol, December 1, 2004; 61(12): 1852 - 1856.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
L. B. Krupp, C. Christodoulou, P. Melville, W. F. Scherl, W. S. MacAllister, and L. E. Elkins
Donepezil improved memory in multiple sclerosis in a randomized clinical trial
Neurology, November 9, 2004; 63(9): 1579 - 1585.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
T. Ohrui, N. Tomita, T. Sato-Nakagawa, T. Matsui, M. Maruyama, K. Niwa, H. Arai, and H. Sasaki
Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression
Neurology, October 12, 2004; 63(7): 1324 - 1325.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
A. P Periclou, D. Ventura, T. Sherman, N. Rao, and W. T Abramowitz
Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil
Ann. Pharmacother., September 1, 2004; 38(9): 1389 - 1394.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
S. Salloway, S. Ferris, A. Kluger, R. Goldman, T. Griesing, D. Kumar, and S. Richardson
Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial
Neurology, August 24, 2004; 63(4): 651 - 657.
[Abstract] [Full Text] [PDF]


Home page
AJGPHome page
C. W. Ritchie, D. Ames, T. Clayton, and R. Lai
Metaanalysis of Randomized Trials of the Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer Disease
Am J Geriatr Psychiatry, August 1, 2004; 12(4): 358 - 369.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
T. Kenakin
Allosteric Modulators: The New Generation of Receptor Antagonist
Mol. Interv., August 1, 2004; 4(4): 222 - 229.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. L. Cummings
Alzheimer's Disease
N. Engl. J. Med., July 1, 2004; 351(1): 56 - 67.
[Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
K Rockwood
Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 677 - 685.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
N. Yasui-Furukori, H. Furukori, A. Kaneda, S. Kaneko, and T. Tateishi
The Effects of Ginkgo biloba Extracts on the Pharmacokinetics and Pharmacodynamics of Donepezil
J. Clin. Pharmacol., May 1, 2004; 44(5): 538 - 542.
[Abstract] [Full Text]


Home page
FocusHome page
J. L. Cummings
Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Focus, April 1, 2004; 2(2): 239 - 252.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
L. J. Beglinger, B. L. Gaydos, D. A. Kareken, O. Tangphao-Daniels, E. R. Siemers, and R. C. Mohs
Neuropsychological Test Performance in Healthy Volunteers Before and After Donepezil Administration
J Psychopharmacol, March 1, 2004; 18(1): 102 - 108.
[Abstract] [PDF]


Home page
Arch NeurolHome page
M. A. Raskind, E. R. Peskind, L. Truyen, P. Kershaw, and C. V. Damaraju
The Cognitive Benefits of Galantamine Are Sustained for at Least 36 Months: A Long-term Extension Trial
Arch Neurol, February 1, 2004; 61(2): 252 - 256.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
S. A. Reines, G. A. Block, J. C. Morris, G. Liu, M. L. Nessly, C. R. Lines, B. A. Norman, and C. C. Baranak
Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study
Neurology, January 13, 2004; 62(1): 66 - 71.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
C. W. Ritchie, A. I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R. Cherny, Q.-X. Li, A. Tammer, et al.
Metal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting A{beta} Amyloid Deposition and Toxicity in Alzheimer Disease: A Pilot Phase 2 Clinical Trial
Arch Neurol, December 1, 2003; 60(12): 1685 - 1691.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
K. R. R. Krishnan, H. C. Charles, P. M. Doraiswamy, J. Mintzer, R. Weisler, X. Yu, C. Perdomo, J. R. Ieni, and S. Rogers
Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer's Disease
Am J Psychiatry, November 1, 2003; 160(11): 2003 - 2011.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. Black, G. C. Roman, D. S. Geldmacher, S. Salloway, J. Hecker, A. Burns, C. Perdomo, D. Kumar, and R. Pratt
Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial
Stroke, October 1, 2003; 34(10): 2323 - 2330.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
K. L. Lanctot, N. Herrmann, K. K. Yau, L. R. Khan, B. A. Liu, M. M. LouLou, and T. R. Einarson
Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis
Can. Med. Assoc. J., September 16, 2003; 169(6): 557 - 564.
[Abstract] [Full Text]


Home page
Br. J. PsychiatryHome page
A. SPECTOR, L. THORGRIMSEN, B. WOODS, L. ROYAN, S. DAVIES, M. BUTTERWORTH, and M. ORRELL
Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: Randomised controlled trial
The British Journal of Psychiatry, September 1, 2003; 183(3): 248 - 254.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
D. Wilkinson, R. Doody, R. Helme, K. Taubman, J. Mintzer, A. Kertesz, and R.D. Pratt
Donepezil in vascular dementia: A randomized, placebo-controlled study
Neurology, August 26, 2003; 61(4): 479 - 486.
[Abstract] [Full Text]</